Image may be NSFW.
Clik here to view.
Bayer (ETR:BAYN) reported last week that its antibiotic drug-device combination product failed in a phase III trial.
In the 725-patient Inhale trial, Bayer’s Amikacin Inhale did not out-perform a placebo as a treatment for Gram-negative pneumonia in patients on ventilators.
Get the full story at our sister site, Drug Delivery Business News.
The post Bayer’s antibiotic drug-device combo fails in late-stage trial appeared first on MassDevice.
